NASOPHARYNGEAL CARCINOMA

This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy before standard treatment can help people with advanced nasopharyngeal cancer live longer without the disease getting worse. About 150 adults with stage T4 or N2-3 cancer will receive either th…

This early-stage study tests a new drug called KFA115, alone or with pembrolizumab, in people with advanced cancers like lung, skin, kidney, and others. The main goal is to find the safest dose and understand side effects. About 126 participants will be enrolled to see if the tre…

This phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 386 adults with advanced nasopharyngeal cancer that has not responded to at least two prior treatments, including immunotherapy. The goal is to see if BL-B01D1 can shrink tumors and help people l…

This phase 3 trial tests whether adding the drug KL-A167 to standard chemotherapy (cisplatin and gemcitabine) helps people with recurrent or metastatic nasopharyngeal carcinoma live longer without their cancer growing. About 295 adults aged 18-75 with this type of nose and throat…

This phase 2 trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) in over 800 people with more than 50 types of rare cancers. The goal is to see if this treatment can shrink tumors by helping the immune system attack cancer cells. The study is for patie…

This study tests whether using smaller radiation targets after chemotherapy can control advanced nasopharyngeal cancer just as well as standard radiation, while causing fewer long-term side effects. About 445 people with stage III to IVa nasopharyngeal cancer will receive chemoth…

This early-phase study tests a new drug (DKY709) alone or with another drug (PDR001) in people with advanced solid tumors like lung cancer, melanoma, and others that have stopped responding to standard treatments. The main goal is to check safety and find the right dose. About 98…

This study tests whether adding the immunotherapy drug sintilimab to the chemotherapy drug capecitabine can help prevent nasopharyngeal cancer from coming back after initial treatment. About 150 adults with advanced-stage disease who did not respond well to induction chemotherapy…

This study tests whether specially trained immune cells from healthy donors can safely fight cancers and diseases caused by the Epstein-Barr virus (EBV). Participants have EBV-positive lymphoma, nasopharyngeal carcinoma, or other EBV-related conditions that returned or didn't res…

This study tests a combination of targeted radiation (SBRT), an immunotherapy drug (PD-1 antibody), and chemotherapy in people with nasopharyngeal cancer that has spread to 5 or fewer spots in the body. The goal is to see if this triple therapy can delay cancer growth and improve…

This study tests if wearing tight gloves and foot caps during chemotherapy can prevent nerve damage (tingling, numbness, pain) caused by the drug paclitaxel. 182 people with nasopharyngeal cancer will wear the pressurized gear on one hand and foot, while the other side serves as …

This study looks at the long-term symptoms and side effects that nasopharyngeal cancer survivors may experience years after finishing radiation and chemotherapy. Researchers will assess quality of life, hearing, hormone levels, and thinking abilities in 108 adults who are cancer-…